BU-NOT-SET

CONTACT US
The QbD approach: Key advantages in clinical and commercial phases
  • Analytical chemistry
Lab
Insight
Sustainability report 2020
  • Sustainability
Report
Report
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
  • Drug substance
Man at poster
Poster
Recipharm Analytical Solutions™
  • Analytical chemistry
Icon
Fact sheet
Impurity identification
  • Analytical chemistry
Woman inserting vials in machine
Fact sheet
Stability studies
  • Analytical chemistry
hand holding vials plate
Fact sheet
Extractables & leachables testing
  • Analytical chemistry
Product mix
Fact sheet
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
  • Industry trends
Eyes
Insight
Global expansion in the CDMO field
  • Industry trends
Eyes
Insight
Case study
  • Drug product
Modified release fixed dose combination product with two poorly soluble drug substances
Insight
  • Drug product
Patient centricity during drug development and commercialisation
Insight
  • Drug product
10 considerations to kick-start your drug development journey
Insight
  • Drug product
Guidance for start-ups on drug development
White paper
  • Drug product
  • Drug substance
Drug development for start-ups
Insight
  • Sustainability
Optimising environmental sustainability
Insight
  • Industry trends
Adapting to deal with the COVID-19 pandemic
Insight
  • Sustainability
On Drug Delivery – Sustainability Q&A
Insight
  • Analytical chemistry
Optimising analytical chemistry to improve speed to market